國立虎尾科技大學 |

Next generation antibody drug conjugates (ADCs) and immunotoxins

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Next generation antibody drug conjugates (ADCs) and immunotoxins/ edited by Ulf Grawunder, Stefan Barth.
其他作者:	Grawunder, Ulf.
出版者:	Cham :Springer International Publishing : : 2017.,
面頁冊數:	xi, 181 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Antibody-toxin conjugates. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-46877-8
ISBN:	9783319468778

Next generation antibody drug conjugates (ADCs) and immunotoxins
Next generation antibody drug conjugates (ADCs) and immunotoxins[electronic resource] /edited by Ulf Grawunder, Stefan Barth. - Cham :Springer International Publishing :2017. - xi, 181 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..

Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P - Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22.

This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.

ISBN: 9783319468778

Standard No.: 10.1007/978-3-319-46877-8doiSubjects--Topical Terms:

1073919
Antibody-toxin conjugates.

LC Class. No.: RS431.A64

Dewey Class. No.: 615.798

Next generation antibody drug conjugates (ADCs) and immunotoxins
LDR:02580nam a2200325 a 4500 001 884495
003 DE-He213
005 20170407150027.0
006 m d
007 cr nn 008maaau
008 180530s2017 gw s 0 eng d
020 $a 9783319468778 $q (electronic bk.)
020 $a 9783319468754 $q (paper)
024 7 $a 10.1007/978-3-319-46877-8 $2 doi
035 $a 978-3-319-46877-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RS431.A64
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.798 $2 23
090 $a RS431.A64 $b N567 2017
245 0 0 $a Next generation antibody drug conjugates (ADCs) and immunotoxins $h [electronic resource] / $c edited by Ulf Grawunder, Stefan Barth.
260 $a Cham : $c 2017. $b Springer International Publishing : $b Imprint: Springer,
300 $a xi, 181 p. : $b ill., digital ; $c 24 cm.
490 1 $a Milestones in drug therapy, $x 2296-6056
505 0 $a Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P - Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22.
520 $a This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
650 0 $a Antibody-toxin conjugates. $3 1073919
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Antibodies. $3 782661
650 2 4 $a Pharmacotherapy. $3 973587
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Oncology. $3 593951
700 1 $a Grawunder, Ulf. $3 1140957
700 1 $a Barth, Stefan. $3 1140958
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Milestones in drug therapy. $3 887606
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46877-8
950 $a Biomedical and Life Sciences (Springer-11642)